Man Group plc Buys Shares of 176,780 Emergent BioSolutions Inc. (NYSE:EBS)

Man Group plc purchased a new position in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 176,780 shares of the biopharmaceutical company's stock, valued at approximately $1,690,000. Man Group plc owned about 0.33% of Emergent BioSolutions at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in EBS. Covestor Ltd lifted its holdings in shares of Emergent BioSolutions by 5,458.5% in the 4th quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 2,893 shares during the last quarter. SBI Securities Co. Ltd. bought a new stake in Emergent BioSolutions during the 4th quarter valued at $63,000. E Fund Management Co. Ltd. bought a new stake in Emergent BioSolutions during the 4th quarter valued at $98,000. EP Wealth Advisors LLC bought a new stake in Emergent BioSolutions during the 4th quarter valued at $110,000. Finally, Alpine Global Management LLC bought a new stake in shares of Emergent BioSolutions in the 4th quarter worth $112,000. Institutional investors own 78.40% of the company's stock.

Insider Activity

In other news, Director Keith Katkin sold 7,844 shares of Emergent BioSolutions stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $6.30, for a total transaction of $49,417.20. Following the transaction, the director now owns 86,431 shares in the company, valued at approximately $544,515.30. The trade was a 8.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Neal Franklin Fowler sold 35,000 shares of Emergent BioSolutions stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the transaction, the director now owns 101,100 shares in the company, valued at $589,413. This represents a 25.72% decrease in their position. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by corporate insiders.

Emergent BioSolutions Trading Up 1.5%

Shares of Emergent BioSolutions stock traded up $0.10 on Thursday, reaching $6.60. 158,313 shares of the company were exchanged, compared to its average volume of 1,221,358. The stock has a fifty day moving average price of $5.28 and a 200-day moving average price of $7.62. The firm has a market capitalization of $357.96 million, a price-to-earnings ratio of -1.61 and a beta of 2.09. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30. Emergent BioSolutions Inc. has a fifty-two week low of $4.02 and a fifty-two week high of $15.10.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.49 by $0.22. The company had revenue of $222.20 million for the quarter, compared to analyst estimates of $218.50 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. On average, analysts expect that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Emergent BioSolutions declared that its Board of Directors has authorized a share repurchase plan on Monday, March 31st that allows the company to buyback $50.00 million in outstanding shares. This buyback authorization allows the biopharmaceutical company to buy up to 19% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research firms have recently commented on EBS. HC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research note on Tuesday, April 1st. Wall Street Zen cut Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.